| Brokerage Reports (Showing 1 to 10 of 17) |
Release Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
StarMine Author Rating | More Info |
| EPS Accuracy * |
Portfolio Return ** |
| 11-Nov-09 | Roth Capital Partners, Inc. | Scott R. Henry CFA, Andrew Vaino | Transition Q1 (FY2010) In-Line, First Half Of 2010 Will Be Transitional | 5 | $10 | | | View Abstract |
| 10-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | MDVN: On track for pivotal AD data in 4-5 months. | 10 | $25 | | | View Abstract |
| 5-Nov-09 | Roth Capital Partners, Inc. | Research Department | Morning Call Summary | 25 | $75 | | | View Abstract |
| 5-Nov-09 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | MDVN: Reports 3Q09 Results – Expecting Connection Trial to Fail In 1H10 | 4 | $10 | | | View Abstract |
| 5-Nov-09 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Andrey Glukhov CFA, Michael Gaugler, Daniel Fidell, Jose Haresco, Bret Jones | Morning Insight (AWR, WRC, AMMD, PFWD, NKTR, CNSO, MDVN, SGMO, ELON, CHG, CNP, NST, NU, UIL, UTL, VVC, THQI) | 16 | $50 | | | View Abstract |
| 5-Nov-09 | Roth Capital Partners, Inc. | Scott R. Henry CFA, Andrew Vaino | BUY Now In Advance Of Phase 3 Dimebon Data in H1 2010 | 8 | $25 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Research Department | Morning Call Summary | 27 | $75 | | | View Abstract |
| 4-Nov-09 | Thomson StreetEvents | N/A | MDVN - Event Transcript of Medivation, Inc. conference call, Nov. 04, 2009 / 4:30pm ET | 15 | $75 | | | View Abstract |
| 3-Nov-09 | Roth Capital Partners, Inc. | Scott R. Henry CFA, Andrew Vaino | 2 More Phase 3 Studies of Dimebon Underway | 3 | $10 | | | View Abstract |
| 29-Oct-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | MDVN: Astellas is a gateway to the large urology market | 10 | $25 | | | View Abstract |